NO2254904T3 - - Google Patents
Info
- Publication number
- NO2254904T3 NO2254904T3 NO09713402A NO09713402A NO2254904T3 NO 2254904 T3 NO2254904 T3 NO 2254904T3 NO 09713402 A NO09713402 A NO 09713402A NO 09713402 A NO09713402 A NO 09713402A NO 2254904 T3 NO2254904 T3 NO 2254904T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
- C12Y306/03044—Xenobiotic-transporting ATPase (3.6.3.44)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Wood Science & Technology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0803352.4A GB0803352D0 (en) | 2008-02-22 | 2008-02-22 | Oligopeptidic compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2254904T3 true NO2254904T3 (pt) | 2018-09-08 |
Family
ID=39284467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO09713402A NO2254904T3 (pt) | 2008-02-22 | 2009-02-20 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US8871724B2 (pt) |
| EP (2) | EP2254904B1 (pt) |
| JP (2) | JP5863240B2 (pt) |
| KR (3) | KR101749204B1 (pt) |
| CN (1) | CN102015758B (pt) |
| AU (1) | AU2009216567B2 (pt) |
| BR (1) | BRPI0908853B1 (pt) |
| CA (1) | CA2715940C (pt) |
| DK (2) | DK3338790T3 (pt) |
| ES (2) | ES2912122T3 (pt) |
| GB (1) | GB0803352D0 (pt) |
| HR (3) | HRP20220585T3 (pt) |
| HU (2) | HUE059174T2 (pt) |
| IL (1) | IL207384B (pt) |
| LT (2) | LT2254904T (pt) |
| MX (1) | MX2010008989A (pt) |
| NO (1) | NO2254904T3 (pt) |
| PL (2) | PL3338790T3 (pt) |
| PT (2) | PT2254904T (pt) |
| RU (1) | RU2549675C2 (pt) |
| TR (1) | TR201807218T4 (pt) |
| WO (1) | WO2009104001A2 (pt) |
| ZA (2) | ZA201005506B (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0803352D0 (en) * | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
| GB201001602D0 (en) * | 2010-02-01 | 2010-03-17 | Cytovation As | Oligopeptidic compounds and uses therof |
| WO2011104309A1 (en) * | 2010-02-24 | 2011-09-01 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compounds for the treatment of inflammation and neutropenia |
| WO2014074847A1 (en) | 2012-11-09 | 2014-05-15 | The Johns Hopkins University | A genetic assay to determine prognosis in polycythemia vera patients |
| WO2014126965A2 (en) | 2013-02-13 | 2014-08-21 | Yale University | Compositions and methods for treating pathological calcification and ossification |
| WO2015055148A1 (zh) * | 2013-10-17 | 2015-04-23 | 上海宝恒泓康生物技术有限公司 | Yap蛋白抑制多肽及其应用 |
| GB201319621D0 (en) | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Antimicrobial agents and their use in therapy |
| GB201319620D0 (en) * | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Immunosuppressive agents and their use in therapy |
| WO2015160529A1 (en) * | 2014-04-02 | 2015-10-22 | Marshall University Research Corportion | Cardiotonic steroid antagonists and related methods |
| HK1243105A1 (en) | 2014-10-17 | 2018-07-06 | 上海宝恒泓康生物技术有限公司 | High activity tumour inhibitor and preparation method and use thereof |
| GB201507722D0 (en) | 2015-05-06 | 2015-06-17 | Norwegian Univ Sci & Tech Ntnu | Anti-bacterial agents and their use in therapy |
| GB201507721D0 (en) * | 2015-05-06 | 2015-06-17 | Norwegian Univ Sci & Tech Ntnu | Immunosuppressive agents and their use in therapy |
| EP4414028A3 (en) | 2015-05-19 | 2024-11-27 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
| EP3377105A4 (en) | 2015-11-20 | 2019-04-24 | Yale University | COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH |
| CA3032467A1 (en) | 2016-08-05 | 2018-02-08 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
| WO2018187515A1 (en) | 2017-04-04 | 2018-10-11 | Avidea Technologies, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| IL254361A0 (en) * | 2017-09-06 | 2017-11-30 | Nat Inst Biotechnology Negev Ltd | Compounds to suppress the methyltransferase setd6 |
| US12134790B2 (en) | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| CN112566672A (zh) * | 2018-05-22 | 2021-03-26 | 阿维迪科技公司 | 制造基于肽的疫苗的改进方法 |
| CN120383683A (zh) | 2018-08-31 | 2025-07-29 | 耶鲁大学 | Enpp1多肽及其使用方法 |
| JP2022512977A (ja) | 2018-11-08 | 2022-02-07 | サメイション バイオ， インコーポレイテッド | ミニヌクレオソームコアタンパク質及び核酸送達における使用 |
| AU2021254697A1 (en) | 2020-04-13 | 2022-11-10 | Summation Bio Inc. | Modified mini-nucleosome core proteins and use in nucleic acid delivery |
| GB202006699D0 (en) | 2020-05-06 | 2020-06-17 | Therapim Pty Ltd | Dosage regimen |
| KR102483938B1 (ko) * | 2020-06-12 | 2023-01-04 | (주)케어젠 | 펜타펩타이드를 유효성분으로 포함하는 항알러지 또는 아토피피부염 개선용 조성물 |
| CN112813042B (zh) * | 2021-02-08 | 2021-08-27 | 南京市妇幼保健院 | 乳腺脂肪组织来源的多肽及其抗肿瘤应用 |
| CN120302959A (zh) * | 2022-07-13 | 2025-07-11 | 欧莱雅 | 修饰肽、组合物、抑制肌肉细胞收缩的方法、改善皮肤的方法和修饰肽的用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2032527C (en) | 1989-04-10 | 2002-07-02 | Jesse M. Jaynes | Lytic peptides: their use in the treatment of microbial infections, cancer and in the promotion of growth |
| JPH04505019A (ja) * | 1989-10-23 | 1992-09-03 | シェリング・コーポレーション | ガンマインターフェロンのポリペプチド性阻害剤 |
| FR2662698A1 (fr) | 1990-06-05 | 1991-12-06 | Centre Nat Rech Scient | Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite. |
| US5888762A (en) | 1990-06-05 | 1999-03-30 | Centre National De La Recherche Scientifique (Cnrs) | Neurotropic growth factors comprising a homeobox peptide |
| AU679167B2 (en) | 1991-09-20 | 1997-06-26 | Amgen, Inc. | Glial derived neurotrophic factor |
| US5534110A (en) | 1993-07-30 | 1996-07-09 | Lam Research Corporation | Shadow clamp |
| CA2173611C (en) | 1993-10-05 | 2005-07-26 | Paul A. M. Van Leeuwen | Method of treating depressed reticuloendothelial system function |
| GB9422175D0 (en) | 1994-11-03 | 1994-12-21 | Univ Dundee | Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof |
| GB9509557D0 (en) * | 1995-05-11 | 1995-07-05 | Univ Dundee | PCNA binding substance |
| FR2739621B1 (fr) | 1995-10-05 | 1997-12-05 | Centre Nat Rech Scient | Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives |
| WO1998041873A1 (en) | 1997-03-14 | 1998-09-24 | The University Court Of The University Of Glasgow | Methods for identifying cell cycle regulators |
| WO1999029721A1 (en) | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
| TWI227136B (en) | 1998-05-21 | 2005-02-01 | Smithkline Beecham Corp | Novel pharmaceutical composition for the prevention and/or treatment of cancer |
| US6368831B1 (en) | 1998-06-29 | 2002-04-09 | Childrens Hospital Los Angeles | Treatment of hyperproliferative disorders |
| AU4724599A (en) | 1998-06-29 | 2000-01-17 | Children's Hospital Of Los Angeles | Treatment of hyperproliferative disorders |
| GB9814527D0 (en) * | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
| US6127177A (en) | 1998-09-11 | 2000-10-03 | Massachusetts Institute Of Technology | Controlled reversible poration for preservation of biological materials |
| AU766489B2 (en) | 1998-11-13 | 2003-10-16 | Cyclacel Limited | Transport vectors |
| WO2001064835A2 (en) * | 2000-02-28 | 2001-09-07 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| WO2000075184A1 (en) | 1999-06-04 | 2000-12-14 | Yale University | Modulation of protein levels using the scf complex |
| US6696263B1 (en) | 1999-09-23 | 2004-02-24 | Rigel Pharmaceuticals, Inc. | PCNA associated cell cycle proteins, compositions and methods of use |
| CN1297923A (zh) | 1999-11-29 | 2001-06-06 | 上海博容基因开发有限公司 | 一种新的多肽——人含细胞色素c结构域的脂蛋白105和编码这种多肽的多核苷酸 |
| GB9928323D0 (en) | 1999-11-30 | 2000-01-26 | Cyclacel Ltd | Peptides |
| WO2001055301A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| JP4503801B2 (ja) * | 2000-09-08 | 2010-07-14 | 独立行政法人科学技術振興機構 | 新規ヒト癌・精巣抗原及びその遺伝子 |
| US6627401B2 (en) * | 2000-12-28 | 2003-09-30 | Council Of Scientific And Industrial Research | Method for detecting a single nucleotide polymorphism in p21waf1/cip1 gene as an indicator of risk of esophageal cancer |
| CA2441562C (en) | 2001-03-28 | 2013-05-14 | Helix Biomedix, Inc. | Short bioactive peptides and methods for their use |
| US6875744B2 (en) | 2001-03-28 | 2005-04-05 | Helix Biomedix, Inc. | Short bioactive peptides |
| US20030114362A1 (en) | 2001-06-08 | 2003-06-19 | Novaspin Biotech Gmbh | Penta-or tetrapeptide binding to somatostatin receptors and the use of the same |
| WO2003042239A1 (en) * | 2001-11-12 | 2003-05-22 | Stichting Sanquin Bloedvoorziening | Peptides inhibiting signaling by ras-like gtpases |
| WO2003051312A2 (en) | 2001-12-18 | 2003-06-26 | Sloan-Kettering Institute For Cancer Research | E2f and cancer therapy |
| US7517857B2 (en) | 2002-01-29 | 2009-04-14 | Posco | Immune-modulating peptide |
| WO2003074003A2 (en) | 2002-03-01 | 2003-09-12 | Applied Immune Technologies | Immunogens for treatment of neoplastic and infectious disease |
| EP1532164B1 (en) * | 2002-08-20 | 2012-09-26 | Polyphor Ltd. | Template-fixed peptidomimetics with antibacterial activity |
| WO2004035732A2 (en) | 2002-08-29 | 2004-04-29 | Five Prime Therapeutics, Inc. | Human polypeptides encoded by polynucleotides and methods of their use |
| JP2006501820A (ja) * | 2002-09-06 | 2006-01-19 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法 |
| AU2003274095A1 (en) * | 2002-10-02 | 2004-04-23 | Theraptosis S.A. | Method for screening modulators of mitochondrial functioning |
| FR2849603B1 (fr) | 2003-01-07 | 2006-09-08 | Centre Nat Rech Scient | Composition pour le transport intracellulaire de macromolecules ou particules biologiques |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| FR2855178B1 (fr) | 2003-05-20 | 2005-08-05 | Centre Nat Rech Scient | Peptides modulateurs de l'activite du facteur de transcription engrailed |
| US7772367B2 (en) * | 2004-01-30 | 2010-08-10 | The Trustees Of Columbia University In The City Of New York | C-terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof |
| JP2008501640A (ja) * | 2004-04-21 | 2008-01-24 | ザ ユニヴァーシティー オヴ シカゴ | ミオシン軽鎖キナーゼ阻害剤及びその使用 |
| GB0410498D0 (en) | 2004-05-11 | 2004-06-16 | Cyclacel Ltd | Crystal |
| US20090176724A1 (en) * | 2004-06-30 | 2009-07-09 | Daiwei Shen | Methods and Compositions for the Diagnosis, Prognosis and Treatment of Cancer |
| SG158153A1 (en) * | 2004-12-21 | 2010-01-29 | Musc Found For Res Dev | Compositions and methods for promoting wound healing and tissue regeneration |
| IN2005CH00851A (pt) * | 2005-07-04 | 2008-01-25 | ||
| WO2007019532A2 (en) | 2005-08-04 | 2007-02-15 | North Carolina State University | Peptide aptamers that bind to the rep proteins of ssdna viruses |
| WO2007049695A1 (ja) * | 2005-10-26 | 2007-05-03 | Chugai Seiyaku Kabushiki Kaisha | 凝集性ｇｌｐ－１アナログおよび徐放性医薬組成物 |
| WO2007098415A2 (en) | 2006-02-17 | 2007-08-30 | Indiana University Research And Technology Corporation | Peptide based inhibition of capcna protein-protein interactions in cancer |
| CU23511B6 (es) | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
| US8440625B2 (en) | 2006-06-26 | 2013-05-14 | University Of British Columbia | Secreted protein acidic and rich in cysteine (SPARC) as chemotherapeutic sensitizers |
| WO2009070642A1 (en) | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
| GB0803352D0 (en) * | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
-
2008
- 2008-02-22 GB GBGB0803352.4A patent/GB0803352D0/en not_active Ceased
-
2009
- 2009-02-20 DK DK18155330.6T patent/DK3338790T3/da active
- 2009-02-20 ES ES18155330T patent/ES2912122T3/es active Active
- 2009-02-20 AU AU2009216567A patent/AU2009216567B2/en active Active
- 2009-02-20 ES ES09713402.7T patent/ES2670334T3/es active Active
- 2009-02-20 EP EP09713402.7A patent/EP2254904B1/en active Active
- 2009-02-20 JP JP2010547249A patent/JP5863240B2/ja active Active
- 2009-02-20 MX MX2010008989A patent/MX2010008989A/es active IP Right Grant
- 2009-02-20 DK DK09713402.7T patent/DK2254904T3/en active
- 2009-02-20 TR TR2018/07218T patent/TR201807218T4/tr unknown
- 2009-02-20 HR HRP20220585TT patent/HRP20220585T3/hr unknown
- 2009-02-20 LT LTEP09713402.7T patent/LT2254904T/lt unknown
- 2009-02-20 PT PT97134027T patent/PT2254904T/pt unknown
- 2009-02-20 KR KR1020167008498A patent/KR101749204B1/ko active Active
- 2009-02-20 NO NO09713402A patent/NO2254904T3/no unknown
- 2009-02-20 WO PCT/GB2009/000489 patent/WO2009104001A2/en not_active Ceased
- 2009-02-20 HU HUE18155330A patent/HUE059174T2/hu unknown
- 2009-02-20 HR HRP20180718TT patent/HRP20180718T1/hr unknown
- 2009-02-20 LT LTEP18155330.6T patent/LT3338790T/lt unknown
- 2009-02-20 RU RU2010134786/10A patent/RU2549675C2/ru active
- 2009-02-20 BR BRPI0908853-9A patent/BRPI0908853B1/pt active IP Right Grant
- 2009-02-20 KR KR1020177003734A patent/KR101758671B1/ko active Active
- 2009-02-20 KR KR1020107020864A patent/KR101653774B1/ko active Active
- 2009-02-20 PL PL18155330T patent/PL3338790T3/pl unknown
- 2009-02-20 CA CA2715940A patent/CA2715940C/en active Active
- 2009-02-20 EP EP18155330.6A patent/EP3338790B1/en active Active
- 2009-02-20 CN CN200980114258.1A patent/CN102015758B/zh active Active
- 2009-02-20 PT PT181553306T patent/PT3338790T/pt unknown
- 2009-02-20 PL PL09713402T patent/PL2254904T3/pl unknown
- 2009-02-20 US US12/918,797 patent/US8871724B2/en active Active
- 2009-02-20 HU HUE09713402A patent/HUE037737T2/hu unknown
-
2010
- 2010-08-02 ZA ZA2010/05506A patent/ZA201005506B/en unknown
- 2010-08-03 IL IL207384A patent/IL207384B/en active IP Right Grant
-
2011
- 2011-08-02 ZA ZA2011/05685A patent/ZA201105685B/en unknown
-
2014
- 2014-09-23 US US14/493,728 patent/US9676822B2/en active Active
-
2015
- 2015-04-28 JP JP2015091311A patent/JP6116614B2/ja active Active
-
2017
- 2017-05-04 US US15/586,653 patent/US10213483B2/en active Active
-
2022
- 2022-05-05 HR HRP20220585 patent/HRP20220585T1/hr unknown